Inhibition of FSCN1 decreases the activity of MAPK pathway, and targeting FSCN1 may inhibit the growth and metastasis of non-small-cell lung adenocarcinoma cells [52]. The gene discussed is FSCN1; the disease is non-small cell lung adenocarcinoma.